ImmuneOnco Achieves Full Enrollment in Phase II Study of IMM01 for CMML
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the successful completion of patient enrollment in its...
Shanghai Bio-Heart Begins RADIUS-HTN Study for Iberis RDN System in France
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced the first patient enrollment...
Shenzhen Hepalink’s OncoVent Secures Licensing Deal with Orient EuroPharma for Oregovomab
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its subsidiary, OncoVent, has...
Kintor Pharmaceutical Realigns Funds from COVID-19 Studies to Other Pipeline Candidates
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced a strategic change in the allocation of...
Pfizer Partners with HCRC to Support ‘Healthy China’ Initiative
US pharmaceutical giant Pfizer (NYSE: PFE) has announced a strategic partnership agreement with China’s Health...
Innovent Biologics Sees 6.7% Revenue Increase in 2022 Amidst R&D Growth and Product Expansion
Biopharmaceutical company Innovent Biologics Inc., (HKG: 1801), has reported revenues of RMB 4.55 billion (USD...
Astellas Pharma Executive Arrested in China on Spying Allegations
A Japanese national and executive at the Chinese division of Tokyo-based Astellas Pharma Inc. (TYO:...
China’s NHSA Introduces Tiered Pricing for COVID-19 Therapies: A, B, and C Categories
The National Healthcare Security Administration (NHSA) has issued a Notification concerning the improvement of the...
Shanghai Pharmaceuticals’ SPH4336 Earns Orphan Drug Status for Liposarcoma Treatment
Shanghai Pharmaceuticals, a leading pharmaceutical company based in China (HKG: 2607, SHA: 601607), has announced...
Junshi Biosciences and Rxilient Biotech Form JV to Commercialize Tuoyi in Southeast Asia
China-based biopharmaceutical company Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a joint venture (JV)...
Novartis’ Kisqali Demonstrates Improved iDFS in Phase III NATALEE Study for Early Breast Cancer
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the multi-center, randomized, open-label Phase III...
Keymed Biosciences’ CM310 Achieves Primary Endpoints in Phase III Atopic Dermatitis Study
China-based Keymed Biosciences Inc., a prominent player in the biopharmaceutical industry (HKG: 2162), has announced...
Broncus Medical and Venus Medtech Establish Joint Venture Fund for Digital Medical Equipment
Broncus Medical Inc., (HKG: 2216) a leading provider of lung disease precision intervention solutions based...
AstraZeneca Plans Tripled R&D Investment in China, Aims for 15 New Drugs by 2030
At the AstraZeneca’s (AZ, NASDAQ: AZN) R&D China Science Day, Yicai Global reported that the...
Burning Rock Reports Q4 2022 Revenue Dip but 10.9% Full-Year Growth
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its financial results for the...
CDE Grants Priority Review Status to TQB3454, HLX208, and Infigratinib for Cancer Treatments
The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQB3454, Henlius...
Brii Biosciences Halts Development of Antibody Cocktail for COVID-19 Treatment
Brii Biosciences has announced a strategic decision to end the manufacturing and further development of...
Berry Genomics Partners with MGI Tech to Advance Cancer Diagnostics and Screening
Chengdu-based Berry Genomics Co., Ltd has announced a strategic partnership with MGI Tech, a subsidiary...
PharmaBlock Expands US Presence with New R&D Facility in West Chester
PharmaBlock, a leading company based in Nanjing (SHE: 300725), has announced the opening of a...
CSPC Pharmaceutical Receives NMPA Approval for Generic Otezla Equivalent
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Celgene’s...